MRO Magazine

Manhattan Scientifics Announces Return of Marvin Maslow as Chairman of the Board


March 25, 2015
By Business Wire News

NEW YORK

Manhattan Scientifics, Inc. (MSI) (OTCQB: MHTX) announced today that Marvin Maslow, founder of MSI, has re-joined the Company’s Board of Directors as Chairman.

MHTX also announced that it has retained Imperial Capital, LLC to explore strategic alternatives for its Metallicum division.

CEO Manny Tsoupanarias said, “In reacquiring our nano-metals technology from our former licensee we believe we added in excess of $10 million in non-cash assets to our balance sheet, plus $8.0 million in cash. We believe our metals technology is more vital now than ever before. Accordingly we retained the M&A services of Imperial Capital, LLC, an investment bank, to explore strategic alternatives to capitalize on our metals technology as it relates to Metallicum Inc.

“I am delighted that Marvin has agreed to return to active duty on the Board. Since stepping down in 2008, Marvin has remained a valuable source of guidance and wisdom to our Company, to our Board, corporately and personally. Marvin’s return to lead the Board of the Company he founded is a reflection of MHTX’s growth and expanding need for talented, experienced management. Marvin is dedicated to assisting management to enhance shareholder value.”

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

About Imperial Capital, LLC

Imperial Capital, founded in 1997, is a full-service investment banking firm with offices in Los Angeles, New York, San Francisco, London, Minneapolis, Boston, Chicago and Houston. The firm currently employs over 250 professionals and offers a wide range of proprietary products and services to institutional investors, middle market companies and private equity firms. Imperial Capital provides institutional clients research and sales and trading of high yield and distressed debt securities, bank debt, convertible bonds, preferred stocks, and equities. The firm provides middle market companies and financial sponsors with capital markets, merger and acquisitions, capital structure, restructuring and recapitalization advisory services. More information about Imperial Capital can be found at www.imperialcapital.com

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Manhattan Scientifics, Inc. PR & IR
Marvin Maslow, 917-923-3300
marvin@mhtx.com
or
Imperial Capital, LLC
Kevin Frisch, 212-351-9704 Ext 2704
Managing Director
Fax: 212-351-9718
KFrisch@imperialcapital.com
or
Corporate Advisory/PR
Fastnet Advisors
Anthony Furey, 631-665-1234
mtfurey@fastnetadvisors.com
or
Hawk Associates
Frank Hawkins, 305-451-1888
f.hawkins@hawkassociates.com
or
European Contact:
Herbert Strauss, +43-316-296-316
herbert “at” eu-ir.com